June 2007

Novel therapeutic approaches represent the latest advances in targeted cancer therapy that may one day provide clinicians with a better means of custom-tailoring cancer treatment. Eventually, treatments may be individualized based on unique sets of molecular targets.

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther toward knowledge and discovery. In this issue: 1) University of Texas M.D. Anderson Cancer Center, Houston, TX: Assessment Model for Lung Cancer Risk 2) Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA: Diabetes Drug Boosts Efficacy of Platinum Chemotherapy Agents, and more

This issue features reports from: American Association for Cancer Research meeting April 14-18, 2007 Los Angeles, CA BIO International Convention May 6-9, 2007 Boston, MA

Topics covered in this issue include: 1) High Cancer Drug Costs Altering the Research and Treatment Dynamic 2) $128 Million Settlement to Physicians 3) Coinsurance Change for Medicare Beneficiaries for Colon Cancer Screening, and more

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Cell Therapeutics' Indolent NHL Agent Gets Fast Tracked 2) First Low-Molecular-Weight Heparin Approved for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer, and more

The Clinical Trials reported in this issue are: PHASE I: CuraGen, TopoTarget Begin Study of HDAC Inhibitor Candidate as Combination Therapy for Soft Tissue Sarcomas Ambrilia%u2019s Therapeutic Peptide Shows Clinical Activity in Metastatic Prostate Cancer Patients PHASE II: Alchemia%u2019s Precursory Evaluation of mCRC Study Presents Positive Efficacy Data IsoRay%u2019s Cesium-131 Established as Front-Line Treatment for Early-Stage Prostate Cancer, and more

Articles in this issue include: 1) Norway: Hopes for Trastuzamab Use in Endometrial Cancer 2) Switzerland: New Guidelines Highlight Use of Bisphosphonates in Elderly Patients With Bone Metastases 3) Italy: Bringing Out All of the Artillery to Fight Mesothelioma, and more

The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women, and more

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.

With so many developments in the biotechnology industry, keeping up-to-date is more important than ever. Oncology & Biotech News is dedicated to helping practicing oncologists stay current on the latest therapeutic breakthroughs.